利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.019 秒)

    ARTIFICIAL FUSION PROTEINS WITH REDUCED IMMUNOGENICITY
    3.
    发明公开
    ARTIFICIAL FUSION PROTEINS WITH REDUCED IMMUNOGENICITY 审中-公开
    免疫原性降低人工融合蛋白

    公开(公告)号：EP1361891A2

    公开(公告)日：2003-11-19

    申请号：EP02700246.8

    申请日：2002-02-18

    申请人： MERCK PATENT GmbH

    发明人： GILLIES, Stephen ,  CARR, Francis, J. ,  JONES, Tim ,  CARTER, Graham ,  HAMILTON, Anita ,  WILLIAMS, Stephen ,  HANLON, Marian ,  WATKINS, John ,  BAKER, Matthew ,  WAY, Jeffrey, C.

    IPC分类号： A61K39/395

    CPC分类号： C07K16/30 ,  C07K16/28 ,  C07K16/2863 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/30

    摘要： The invention relates to artificial modified proteins, preferably fusion proteins, having a reduced immunogenicity compared to the parent non-modified molecule when exposed to a species in vivo. The invention relates, above all, to novel immunoglobulin fusion proteins which essentially consist of an immunoglobulin molecule or a fragment thereof covalently fused via its C-terminus to the N-terminus of a biologically active non-immunoglobulin molecule, preferably a polypeptide or protein or a biologically active fragment thereof. In a specific embodiment, the invention relates to fusion proteins consisting of an Fc portion of an antibody which is fused as mentioned to the non-immunological target molecule which elicits biological or pharmacological efficacy. The molecules of the invention have amino acid sequences which are altered in one or more amino acid residue positions but have in principal the same biological activity as compared with the non-altered molecules. The changes are made in regions of the molecules which are identified as T-cell epitopes, which contribute to an immune reaction in a living host. Thus, the invention also relates to a novel method of making such fusion proteins by identifying said epitopes comprising calculation of T-cell epitope values for MHC Class II molecule binding sites in a peptide by computer-aided methods.